Oncimmune have seen highly encouraging cost-effectiveness study data for its EarlyCDT Lung test in the diagnosis of lung cancer patients that it will be able to leverage in ongoing adoption discussions with healthcare providers. The study shows that at a reimbursed price of £70/test, EarlyCDT Lung test use in combination with Computed Tomography (CT) compared to CT surveillance alone (the current standard of care), produced an incremental cost-effectiveness ratio (ICER) of £2,417/quality adjuste ....
03 Sep 2020
EarlyCDT Lung blood test use shown to be highly cost-effective
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
EarlyCDT Lung blood test use shown to be highly cost-effective
Oncimmune Holdings Plc (ONC:LON) | 26.4 0 0.0% | Mkt Cap: 19.6m
- Published:
03 Sep 2020 -
Author:
Edward Thomason -
Pages:
4
Oncimmune have seen highly encouraging cost-effectiveness study data for its EarlyCDT Lung test in the diagnosis of lung cancer patients that it will be able to leverage in ongoing adoption discussions with healthcare providers. The study shows that at a reimbursed price of £70/test, EarlyCDT Lung test use in combination with Computed Tomography (CT) compared to CT surveillance alone (the current standard of care), produced an incremental cost-effectiveness ratio (ICER) of £2,417/quality adjuste ....